Prophylactic chemotherapy is vitally important for emergency patients with serious diseases since infections are readily caused by contamination with indigenous bacteria, especially gram-positive cocci, in the emergency treatment of wounds and various kinds of diseases. We primarily administered cefazolin (CEZ), a first-generation cephem antibiotic, to 78 patients who were transferred to the intensive care unit at our emergency medical facility and who were exposed to contamination or infection with these bacteria, to evaluate the prophylactic effect of CEZ against infection with them. Infections did not occur in 55 (70.5%) of these patients after administration, but did occur in 28 (29.5%), by about the 10th day in hospital. Therefore, substituting other antibiotics for CEZ was required in these patiens. However, gram-positive cocci regarded as indigenous were not detected, even in the infected patients. The primary effect of CEZ against infection with indigenous bacteria was confirmed. Infections were observed in most of the patients with serious diseases and were considered to be due to decreased immunocompetence. Gram-positive cocci with multi-drug resistance, especially methicillin-resistant
Staphylococcus aureus (MRSA), accounted for 72.2% of the causative organisms. The infections might have been predisposed to by the primary administration of CEZ. However, all of these organisms were resistant to the beta-lactam antibiotics, so these infections were nosocomial, developing after admission to hospital, and prevention of the onset was difficult. Thereafter these patients responded well to vancomycin, so the infections were not considered to be due to problems associated with primary administration of CEZ. Therefore, when the possibility of new drug resistance, the drug price, and the effects of the drugs on indigenous bacterial flora are considered, bearing in mind that these were nosocomial infections, the use of first-generation cephems is considered to be prefered for primary administration, even in emergency patients with serious diseases and decreased immunocompetence.
View full abstract